Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510, 520, 522, 524, and 556
[Docket No. FDA-2014-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule, technical amendment.
 SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during August 2014. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a change of sponsorship of two NADAs and one ANADA, and to reflect a revised food safety warning.
 DATES: This rule is effective October 28, 2014.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, 
                        *george.haibel@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during August 2014, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: 
                    *http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm.*
                     Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: 
                    *http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.* In addition, Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort Collins, CO 80525 has transferred ownership of, and all rights and interest in ANADA 200-033 for UNIPRIM (trimethoprim and sulfadiazine) Powder to Neogen Corp. (Neogen), 944 Nandino Blvd., Lexington, KY 40511. In 2004, Hess & Clark, Inc., transferred ownership of, and all rights and interest in NADA 011-154 for NFZ Puffer (nitrofurazone soluble powder) and NADA 140-851 for NFZ Wound Dressing (nitrofurazone ointment) to Neogen. At this time, the regulations are being amended to reflect these transfers. Following these changes of sponsorship, Macleod Pharmaceuticals, Inc., and Hess & Clark, Inc., will no longer be the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for these firms. Also, the animal drug regulations are being amended in 21 CFR 522.690 to revise a human food safety warning for dinoprost tromethamine injectable solution. This amendment is being made to improve the accuracy of the regulations. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. Table 1—Original and Supplemental NADAs and ANADAs Approved During August 2014
NADA/ANADA
Sponsor
New animal drug 
                             product name
Action
21 CFR 
                             Sections
FOIA 
                             Summary
NEPA Review140-833
Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640
IVOMEC Plus (ivermectin and clorsulon) Injection for Cattle
Supplemental approval reducing the preslaughter withdrawal period from 49 days to 21 days
522.1193
                             556.344
yes
CE.1 2141-043
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007
SYNOVEX CHOICE (trenbolone and estradiol implant)
Supplemental approval for increased rate of weight gain and improved feed efficiency in heifers fed in confinement for slaughter
522.2478
yes
EA/FONSI.3141-342
Jurox Pty. Ltd., 85 Gardiner Rd., Rutherford, NSW 2320, Australia
ALFAXAN (alfaxalone)  Injectable Anesthetic for Dogs and Cats
Supplemental approval adding a label statement that alfaxalone is a Class IV controlled substance
522.52
no
CE.1 4( print page 64115)141-348
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007
SYNOVEX ONE FEEDLOT (trenbolone and estradiol extended release implant)
                             SYNOVEX ONE GRASS (trenbolone and estradiol extended release implant)
Original approval for increased rate of weight gain and improved feed efficiency for up to 200 days in steers and heifers fed in confinement for slaughter
                             Original approval for increased rate of weight gain for up to 200 days in pasture steers and heifers (slaughter, stocker, and feeder)
522.2478
yes
EA/FONSI.1 3200-455 5
Cross Vetpharm Group Ltd. Broomhill Rd., Tallaght,
                             Dublin 24, Ireland
TYLOMED-WS (tylosin tartrate) Soluble Powder
Supplemental approval of a change to veterinary prescription (Rx) marketing status to conform with reference (pioneer) product
520.2640
no
CE.1 61
                         The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment.2
                         CE granted under 21 CFR 25.33(a).3
                         The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI).4
                         CE granted under 21 CFR 25.33(d)(1).5
                         This application was listed as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013.6
                         CE granted under 21 CFR 25.33(a)(1).
 List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, and 524 Animal drugs 21 CFR Part 556 Animal drugs
Foods
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 556 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.The authority citation for 21 CFR part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.In § 510.600, in the table in paragraph (c)(1), remove the entries for “Macleod Pharmaceuticals, Inc.” and “Hess & Clark, Inc.” and alphabetically add an entry for “Neogen Corp.”; and in the table in paragraph (c)(2), remove the entries for “058711” and “050749” and numerically add an entry for “059051” to read as follows: § 510.600
  
 (c) * * * (1) * * * Firm name and address
Drug labeler code*         *         *         *         *         *         *Neogen Corp., 944 Nandino Blvd., Lexington, KY 40511
059051*         *         *         *         *         *         *
 (2) * * * Drug labeler code
Firm name and address*         *         *         *         *         *         *059051
Neogen Corp., 944 Nandino Blvd., Lexington, KY 40511( print page 64116)*         *         *         *         *         *         *
 PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 3.The authority citation for 21 CFR part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 520.2613
 4.In paragraph (b) of § 520.2613, remove “058711” and in its place add “059051”. 5.In § 520.2640, revise paragraphs (b), (d), and (e)(2)(ii) to read as follows: § 520.2640
  
 (b) 
                            *Sponsors*
                            —(1) No. 000986 for use as in paragraph (e) of this section. (2) Nos. 016592 and 061623 for use as in paragraphs (e)(1)(i)(A), (e)(1)(ii), (e)(2), (e)(3), and (e)(4) of this section. 
 (d) 
                            *Special considerations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian. (e) * * * (2) * * * (ii) 
                            *Indications for use.*
                             For the reduction in severity of effects of infectious sinusitis associated with 
                            *Mycoplasma gallisepticum.*
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 6.The authority citation for 21 CFR part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. 7.In § 522.52, in paragraph (c)(3), add a second sentence to read as follows: § 522.52
  
 (c) * * * (3) * * * Alfaxalone is a Class IV controlled substance.
 8.In § 522.690, revise paragraph (d)(1)(iii) to read as follows: § 522.690
  
 (d) * * * (1) * * * (iii) 
                            *Limitations.*
                             Do not use in horses intended for human consumption.
 9.In § 522.1193, revise paragraph (e)(3) to read as follows: § 522.1193
  
 (e) * * * (3) 
                            *Limitations.*
                             For No. 050604: Do not treat cattle within 21 days of slaughter. For Nos. 055529 and 058005: Do not treat cattle within 49 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.
 10.In § 522.2478, revise paragraphs (a), (d)(1)(i) introductory text, (d)(1)(ii) introductory text, and (d)(2); and add paragraphs (d)(1)(iii) and (d)(3) to read as follows: § 522.2478
  (a) 
                            *Specifications*
                            —(1) Each implant consists of: (i) 8 pellets, each pellet containing 25 milligrams (mg) trenbolone acetate and 3.5 mg estradiol benzoate. (ii) 4 pellets, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate. (2) Each extended release implant consists of: (i) 8 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate. (ii) 6 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate. 
 (d) * * * (1) * * * (i) For an implant as described in paragraph (a)(1)(i) of this section: 
 (ii) For an implant as described in paragraph (a)(1)(ii) of this section: 
 (iii) For an implant as described in paragraph (a)(2)(i) of this section: (A) 
                            *Amount.*
                             200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant. (B) 
                            *Indications for use.*
                             For increased rate of weight gain and improved feed efficiency for up to 200 days. (C) 
                            *Limitations.*
                             Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. (2) 
                            *Heifers fed in confinement for slaughter*
                            —(i) For an implant as described in paragraph (a)(1)(i) of this section: (A) 
                            *Amount.*
                             200 mg trenbolone acetate and 28 mg estradiol benzoate. (B) 
                            *Indications for use.*
                             For increased rate of weight gain. (C) 
                            *Limitations.*
                             Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. (ii) For an implant as described in paragraph (a)(1)(ii) of this section: (A) 
                            *Amount.*
                             100 mg trenbolone acetate and 14 mg estradiol benzoate. (B) 
                            *Indications for use.*
                             For increased rate of weight gain and improved feed efficiency. (C) 
                            *Limitations.*
                             Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. (iii) For an implant as described in paragraph (a)(2)(i) of this section: (A) 
                            *Amount.*
                             200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant. (B) 
                            *Indications for use.*
                             For increased rate of weight gain and improved feed efficiency for up to 200 days. (C) 
                            *Limitations.*
                             Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. (3) 
                            *Pasture steers and heifers (slaughter, stocker, and feeder)*
                            —(i) For an implant as described in paragraph (a)(2)(ii) of this section: (A) 
                            *Amount.*
                             150 mg trenbolone acetate and 21 mg estradiol benzoate in an extended release implant. (B) 
                            *Indications for use.*
                             For increased rate of weight gain for up to 200 days. (C) 
                            *Limitations.*
                             Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. 
                            ( print page 64117)
                            Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. (ii) [Reserved]
 PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 11.The authority citation for 21 CFR part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 524.1580a
 12.In paragraph (b)(1) of § 524.1580a, remove “Nos. 050749, 054628, 054925, 058005, and 061623” and add in its place “Nos. 054628, 054925, 058005, 059051, and 061623”. § 524.1580b
 13.In paragraph (b) of § 524.1580b, remove “No. 054628” and in its place add “Nos. 054628 and 059051”. PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 14.The authority citation for 21 CFR part 556 continues to read as follows: Authority:
                        21 U.S.C. 342, 360b, 371. 15.In § 556.344, revise paragraphs (a), (b)(1)(i), and (b)(2)(ii); and add paragraph (c) to read as follows: § 556.344
  (a) 
                            *Acceptable Daily Intake (ADI).*
                             The ADI for total residues of ivermectin is 5 micrograms per kilogram of body weight per day. (b) * * * (1) * * * (i) 
                            *Cattle.*
                             1.6 parts per million. (2) * * * (ii) 
                            *Cattle.*
                             650 parts per billion. (c) 
                            *Related conditions of use.*
                             See §§ 520.1192, 520.1195, 520.1197, 522.1192, 522.1193, 524.1193, and 558.300 of this chapter.
 Dated: 
                        *October 23, 2014.* Bernadette Dunham, Director, Center for Veterinary Medicine.


[FR Doc. 2014-25588 Filed 10-27-14; 8:45 am] BILLING CODE 4164-01-P